Novartis and Merck: Evaluating Dividend Stability in Big Pharma

Investors seeking stable income are increasingly looking toward the pharmaceutical sector, where consistent demand for life-saving therapies often supports reliable dividend growth. Merck (MRK) and Novartis (NVS) stand out as two of the industry's most prominent options, both having outperformed the S&P 500 over the last 12 months. Merck continues to leverage Keytruda, the world's top-selling cancer drug. To combat upcoming patent expirations, the company has secured approval for a subcutaneous version of the drug to maintain market share. Additionally, Winrevair surpassed $1 billion in annual sales in 2025, and the new pneumonia vaccine Capvaxive is showing strong growth. Merck offers a 2.9% forward dividend yield, with payouts growing 93.8% over the last decade. Novartis is navigating the loss of U.S. patent exclusivity for its heart failure drug, Entresto, by relying on a highly diversified portfolio. The company boasts 15 medicines with annual sales exceeding $1 billion, including the rapidly growing Fabhalta. Novartis projects continued sales growth into 2026, supported by a robust pipeline. Its dividend program is particularly stable, featuring a 3.1% forward yield and a streak of annual increases dating back to 1996. While both firms are viable for income seekers, Novartis presents a slightly more resilient profile due to its lower dependence on a single blockbuster drug. Merck's reliance on Keytruda creates a more concentrated risk profile as the company approaches a significant patent cliff within the next two years.